

Market Announcement

25 September 2023

Botanix Pharmaceuticals Ltd (ASX: BOT) - Trading Halt

Description

The securities of Botanix Pharmaceuticals Ltd ('BOT') will be placed in trading halt at the request of BOT, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Wednesday, 27 September 2023 or when the announcement is released to the market.

Issued by

Scarlette de Lavaine Adviser, Listings Compliance



25 September 2023

Company Announcements
Australian Securities Exchange
Level 40
Central Park
152 – 158 St Georges Terrace
PERTH WA 6000

Dear Sir/Madam

Request for Trading Halt

Pursuant to ASX Listing Rule 17.1, the Directors of Botanix Pharmaceuticals Limited (ASX: BOT) ("Botanix" or "the Company") request an immediate trading halt in the securities of the Company pending release of an announcement regarding US Food and Drug Administration (FDA) communication in respect of the Botanix New Drug Application (NDA) for Sofpironium Bromide gel, for the treatment of primary axillary hyperhidrosis (excessive sweating).

This trading halt will be in place until release of the Botanix announcement, expected no later than open of trading on Wednesday 27 September 2023.

The Company is not aware of any reason why the trading halt should not be granted, nor any other information necessary to inform the market about the trading halt.

By order of the Board

Susan Park

Company Secretary

For more information, please contact:

General enquiries

Corporate Communications Botanix Pharmaceuticals P: +61 8 6555 2945

investors@botanixpharma.com

Investor enquiries

Hannah Howlett WE Communications P: +61 450 648 064

hhowlett@we-worldwide.com

Media enquiries

Haley Chartres H^CK

P: +61 423 139 163 haley@hck.digital